Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue is expected to release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Kenvue, which was spun off from Johnson & Johnson in 2023, has been working to shore up profitability, especially in its ...

Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts.

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

By Pushkala Aripaka and Emma Rumney (Reuters) -Diageo CEO Debra Crew has stepped down after two years in the job, the world's biggest spirits maker said on Wednesday, with finance chief Nik Jhangiani ...

Shoppers aged 45 to 60 now make up 25% of total spend for the beauty category, favouring products that ‘balance benefits with ...

Diageo CEO Debra Crew has stepped down after just two years in the job, the world's biggest spirits maker said.